Sunday 29 November 2015
NewBridge Pharmaceuticals

Firm to market breast cancer drug in ME

Japan-based Eisai will market its breast cancer treatment Halaven (eribulin) in selected countries within the Middle East region through a new partnership between Eisai EMEA and NewBridge Pharmaceuticals. Eribulin is indicated for


NewBridge inks Abstral distribution deal

Dubai-based NewBridge Pharmaceuticals has signed an exclusive licensing and distribution agreement with Orexo AB to market Abstral, a key product for treatment of breakthrough cancer pain, in the Middle East and Africa region. A specialty


NewBridge raises $12 million financing

The Dubai-based NewBridge Pharmaceuticals has completed its $12 million Series B financing, bringing the total amount raised to $16 million. NewBridge also announced today the appointment of Joseph W Henein as its president and chief execu

 1 2 3 4 5 >  Last ›

calendarCalendar of Events